| INTRODUCTION
The aim of allergic rhinitis (AR) management is to achieve control of the disease and its symptoms 1, 2 and is a dynamic process. Control can fluctuate over time influenced by many factors, including AR phenotype (ie intermittent or persistent AR), environmental exposure and current treatment. Therefore, the tool used to measure disease control must be simple, suitable for everyday use and sensitive to change. A simple visual analogue scale (VAS) has been recommended as the language for assessing AR control. [2] [3] [4] It has recently been converted to electronic format and included in a free mobile app for patients-Allergy Diary-as part of MASK (Mobile Airways Sentinel network). [5] [6] [7] [8] The Allergy Diary aims to empower patients to self-manage their AR. 5, 6 The use of self-management and information and communication technology may hold the key to chronic disease management and provides useful objective data for physicians.
The VAS has also been incorporated into an AR clinical decision support system (CDSS), a new type of disease management tool. 2 A CDSS is a health information technology system, based on the best evidence and algorithms, designed to provide physicians, and other healthcare providers, with clinical decision support (ie assistance with clinical decision-making tasks). It is an important tool for precision medicine. 9, 10 Within the AR CDSS, the VAS is used to assess AR control and to assist in making management decisions, assisting patients and healthcare providers to jointly determine AR treatment and its step-up or step-down strategy depending on the status of AR control. Figure 1 outlines the six steps involved in the transformation of the paper AR CDSS ( Figure S1A and B) 2 to the e-CDSS.
| METHODS

| Step 1: Major scenarios on AR management approach
Thirteen major scenarios were identified from the AR CDSS (Table   S1 ). These scenarios incorporated VAS score cut-offs, ARIA-defined AR phenotype (ie intermittent or persistent AR) and AR treatment, and provided an AR management approach (ie when to initiate treatment, continue, step-up and step-down treatment). T0 represents no treatment. For the purpose of these scenarios, AR treatments were coded as follows:
• T1: Non-sedating H 1 -antihistamines (oral, intranasal and intraocular), leukotriene receptor antagonists (LTRA) and cromones (intranasal or intraocular) • T2: Intranasal corticosteroid (INCS)
• T3: INCS + azelastine (AZE)
• T4: Oral corticosteroids (as add on to local treatment)
• T5: Consider referral to an allergist and allergen immunotherapy
The AR CDSS is an algorithm for the acute symptomatic treatment of AR. Recommendations on the benefits and use of AIT may be found elsewhere. 
| Step 2: Specific AR treatment recommendations
From these 13 major scenarios, 34 detailed scenarios were developed. 2 Inputs considered included disease phenotype (ie intermittent/persistent), allergen exposure, VAS score and current treatment and specific AR management recommendations were provided (Tables S2-S5 ).
| Step 3: Survey of experts
These 34 detailed scenarios were incorporated into a survey that was delivered by an online service, Survey Monkey (www.survey monkey.com), and sent to 70 experts on AR and ARIA members from 23 countries, in order to achieve consensus and improve robustness of the AR CDSS algorithm. Experts were selected for their expertise (ie general practice, allergy, ENT, respiratory medicine, pharmacy and public health) with a global representation. We aimed at a 50% response rate. The survey was divided into 4 parts:
(a) general approach to AR treatment (ie when to initiate, continue, step-up or step-down treatment; n = 8 questions; (Table S3 ; Figure S2A ). Excellent expert consensus was also achieved for all step-down scenarios except scenarios 20 (survey VAS score:
74 mm) and 21 (survey VAS score: 66 mm) which dealt with step-down from T3 or T2, respectively (Table S4 ; Figure S2A ). The reasons for these lower consensus scores and resolution of these issues are provided in the online Supporting information.
| Step 4: Scenario modification and summary of findings
An email was sent to all experts who provided a survey VAS score <50 mm for any scenario to (a) understand the reason for 
| Step 6: Programming
Finally, a total of 77 scenarios (all possible scenarios) were programmed into the Allergy Diary Companion. The app was programmed and designed by Peercode, Netherlands, using the digital specifications above (including expert treatment recommendations), ensuring consideration of each possible input into the app. It was developed in Titanium Appcelerator (JavaScript) for tablets on the IOS platform and is easily translated and modified. Usability of the app and reliability of the treatment recommendations it provides has been checked by Peercode and further validation is currently ongoing prior to launch.
The app requires no Internet function after download.
| RESULTS
| Summary of survey results
Mean scores for each question were calculated to show the level of consensus for each of the 34 AR CDSS scenarios (Table 1 and • AR treatment should be stepped-up for treated AR patients with a VAS score ≥5/10 cm.
• For patients with VAS score ≥2 to <5/10 cm, treatment should be continued for patients with intermittent AR (IAR) and continued or stepped-up for those with persistent AR (PER).
• Treatment should be stepped-down for patients with a VAS score <2/10 cm.
• When step-up treatment is recommended, patients on T1 should be stepped up to T2 OR T3.
• When step-up treatment is recommended, patients on T2 should be stepped up to T3.
• Short course oral corticosteroids (ie T4) may be added here if necessary.
• Patients should be referred (eg to ENT or allergy specialists) if VAS score remains ≥ 5/10 cm or if there is a need for oral corticosteroids.
• When step-up treatment is recommended, patients on multiple therapies should be stepped up to T3 and T4 added on (short course to minimize side-effects and only if necessary).
• Stepping-down treatment was essentially the same in reverse, with the proviso that patients with nasal congestion should be stepped-down to an INCS-containing regimen in preference to T1 (albeit many patients will self-medicate and stop treatment).** • Treatment step-up and step-down strategies remain the same irrespective of AIT status.* *: Does not consider the indication of AIT. **: Modified after expert consensus.
| Digital specification of the e-CDSS modules
To make a treatment recommendation, the CDSS within the Allergy Diary Companion must be "fed" with information. We have described this information as modules ( Table 2 ) with each of modules 1, 2 and 3 providing the input necessary for module 4 (ie e-CDSS).
| Module 1 (VAS score)
During physician consultation or pharmacist visit, patients generate a VAS score using their finger and the touchscreen functionality of an iPad, allowing selection of VAS score from 0 to 10 cm (inclusive).
For the purpose of the e-CDSS, VAS scores are categorized as ≥5/ 10 cm (uncontrolled AR), ≥2 to <5/10 cm (partly controlled AR) and <2/10 cm (well-controlled AR) (Table 2) , the same as those cut-offs used by Allergy Diary. These cut-offs were selected based on clinical studies in both asthma and rhinitis.
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| Module 2 (treatment classification system)
The purpose of this module is to define the class(es) of current AR medications used by patients. A simple alphanumeric system was used for the e-CDSS, with treatments classified from T0 (no treatment) up to T5 (consider referral and AIT) ( Table 2) .
(A) (B)
F I G U R E 2 Decision processes underlying treatment recommendations for (A) patients not currently on any AR medication, (B) patients with well-controlled AR (ie VAS score <2/10 cm), (C) patients with partly controlled AR (ie VAS score ≥2 to <5/10 cm) and (D) patients with uncontrolled AR (ie VAS score ≥ 5/10 cm). AR, allergic rhinitis; VAS, visual analogue scale; M1, module 1; M2, module 2; M3, module 3; Ti, class of current treatment (in case of polypharmacy, Ti = maximum class). Tj, Tk and Tl, medications added to Ti, order of class l < k < j < i. T1, antihistamine (oral, intranasal and eye drops), leukotriene receptor antagonist, cromone (intranasal and eye drops); T2, intranasal corticosteroid (INCS); T3, INCS + Azelastine; T4 add short course of oral corticosteroids; T5, consider referral and allergen-specific immunotherapy Table 2 ). Multiple medication selections are permitted. For each medication class selected, a corresponding treatment code is assigned by the system. Exposure to allergen is assessed using a simple true or false algorithm (Table 2 ). Figure S4 shows the organogram of the sequence of questions that patients answer in Module 3. At any step, the patient can go back to a previous question to correct his/her answer, or cancel the survey answer. No personal information is collected.
| Module 4 (e-CDSS specifications)
The e-CDSS uses data obtained from the other modules to deliver a recommendation corresponding to the most appropriate treatment. Table 2 summarizes how this information is gathered, the input used by the e-CDSS to make a decision and the variables used (online Supporting information). Information from each of these modules is used to produce treatment recommendations. The decision processes underlying treatment recommendations are shown in Figure 2 (A-D). Four decision processes were developed to cover 4 scenarios: (a) the patient is not currently on any AR medication (Figure 2A), (b) the patient has well-controlled AR (ie VAS score <2 cm; Figure 2B ), (c) the patient has partly controlled AR (ie VAS score ≥2 to <5 cm; Figure 2C ) and (d) the patient has uncontrolled AR (ie VAS score ≥ 5 cm; Figure 2D ).
| Interfaces specifications
| Collecting information
Allergy Diary Companion screen interfaces for collecting VAS score
for the e-CDSS is shown in Figure 3A . The VAS question is "overall Figure S5 .
T A B L E 2 Modules of e-CDSS
Info
Description e-CDSS decision or input e-CDSS variable
| Summarizing information
The following information is summarized by Allergy Diary Companion for providers ( Figure 3B ): Figure 3B ).
• AR phenotype: This is categorized as either "intermittent" or "persistent" depending on the duration of treatment (or symptoms).
• Allergen exposure: summarized as either "yes" or "no"
• Treatment: List of currently taken AR treatments.
| Treatment recommendation
A treatment recommendation is then provided based on this information, and using the rules as outlined in the e-CDSS (Figures 2A-D ) and summarized in Table 1 . Treatment recommendations are in the format: Recommendation-approach-specific treatment recommendation. For the example shown in Figure 3B , the recommendation is to step-up treatment, as the patient has a VAS score ≥5/ 10 cm, has IAR (with allergen exposure) and is currently treated (with AIT and FP-ie T5 + T2)-see Table 1 
| DISCUSSION
In this article, we describe a 21st century approach to AR management. m-Health refers to the use of mobile devices to collect, collate and assess patient level health data. In this article, we focus on CDSS and m-health in AR and describe the process of transforming the recently published AR CDSS 2 into an e-CDSS, and how this e-CDSS was embedded into an m-health tool for providers called the guidelines is poor 21 and it is hoped that when guideline recommendations are presented electronically, providers may make safer prescribing decisions and adhere more closely to these recommendations vs peers using paper resources. 22 Unfortunately, at the physician level CDSSs are rarely used, and the advice is not followed, 23 even though use of computerized CDSSs have been shown to improve asthma and COPD care. 24 Embedding the AR CDSS into the Allergy Diary Companion is expected to increase usage of the AR CDSS, resulting in improved standard of AR care in routine clinical practice, both at the physician and pharmacy levels.
Allergy Diary Companion.
Incorporation of the e-CDSS into the
Indeed, CDSSs have already proved beneficial at the pharmacy level, 25, 26 reducing the frequency of drug-drug interactions and preventing inappropriate prescribing and underprescribing. 27 It should also be noted that although a recently conducted Cochrane review provided no evidence that the use of electronic health information (EHI) translates into improved clinical practice or patient outcomes, it does suggest that when practitioners are provided with EHI and education or training, its use increases. 28 It was further noted that for EHI to be applied in patient care, it will be necessary to understand why practitioners' are reluctant to apply EHI when treating people and to determine the most effective way(s) to reduce this reluctance. On the patient side, mobile phone apps to improve allergy and asthma care are part of an ever-growing number of m-tools available, but their usefulness is still debated and studies have been small. 29, 30 However, a large study including 327 individuals with AR or asthma,
showed that QoL was improved in AR patients and the likelihood of asthma control increased when using an app which facilitated communication with physicians and which recorded health status and medication compliance. Guidance already exists on data protection requirements for "apps" Allergy Diary Companion app functionally and management advice needs to be validated, and this will be done prior to launch. The Allergy Diary Companion app is an ideal tool to assess the benefit of using the AR CDSS in a real-life setting. The value of this m-health tool is that it allows for variations and modifications of the e-CDSS based on real-life experience, thus moving from a consensus-based CDSS to an evidence-based one.
Other modules which may be used to "feed" the e-CDSS could include identification of those patients at risk of allergen exposure by incorporating a pollen alert module (Module 6; Figure 4 ) and a sentinel network module (Module 7; Figure 4 ). The sentinel network is an early warning system or predictor for patients of impending symptoms. A recently obtained H2020 grant (POLLAR: Impact of air pollution in asthma and rhinitis) will help to answer this question.
This system should also prove useful in predicting asthma control deterioration in those with comorbid rhinitis. Use of predictive algorithms have already been used in home monitoring of asthma and chronic obstructive pulmonary disease patients, but with varying degrees of success, mainly due to poor patient compliance and poor performance of conventional algorithms for detecting deteriorations. 32 These improvements to the system would essentially negate the need for Modules 1 and 3 for those users with smartphones.
Modules 1 and 3 would remain in the system for those patients who do not have a smartphone or do not wish to download Allergy Diary.
Finally, a PC-based tool should also be developed, enabling physicians to import data, with individual patient consent, to their pc directly from the patient's Allergy Diary, interacting with Allergy Diary
Companion, so that data may be stored as an electronic file as part of the patient's notes.
When developing any new m-health tool, the aim is to achieve a high quality and popular app, which will be used enthusiastically and provide benefit to users. This is a challenging process, and not 35 MASK complies with equity (design and implementation), practice (eg appropriateness of design and SMART objectives), ethical, evaluation, empowerment/participation, target population, sustainability, governance and scalability targets. 35 Use of both apps will (a) permit patients to screen for allergic disease and monitor AR and asthma control, (b) assist pharmacists in recommending over the counter medications and prompt referral of patients with uncontrolled AR to physicians and (c) encourage primary care physicians to prescribe appropriate treatment, to followup in accordance with the AR CDSS and to refer to specialist clinics when appropriate. 36 However, the e-CDSS does not include information on allergic multimorbidities. 37 That will be included at a later stage.
In conclusion, the Allergy Diary Companion for providers has been designed to provide healthcare information to practitioners and researchers, to permit real-time monitoring of disease-related data and to provide guideline and expert-endorsed AR treatment recommendations. The Allergy Diary Companion is currently being finalized and will be launched in 2018.
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